New drugs for the treatment of multiple myeloma patients

Multiple myeloma is a cancer of bone marrow plasma cells. Plasma cells produce certain proteins that establish the immune system. According to research using recombinant dog proteins, when the number shows abnormalities, these proteins damage the body and the immune system.

"We are now able to diagnose and treat myeloma earlier before it begins to damage the body, thus effectively controlling myeloma, and any irreversible damage to the body may be significantly delayed," said Dr. Sikander Ailawadhi, haematologist and oncologist from Jacksonville Mayo Clinic Cancer Center.

In 2015, the US Food and Drug Administration approved three new drugs for the treatment of multiple myeloma in two weeks. "The approval of these drugs for the treatment of diseases that are considered to be incurable in such a short period of time is unprecedented," Ailawadhi said. "Most patients showed symptom relief, and their survival rate has been improved."

"We can almost guarantee that every patient who has been diagnosed with newly diagnosed myeloma has a certain degree of reaction," he added.

"Some of the most exciting things are the development of new drugs," Ailawadhi explained. "Specifically, we can use the currently available drugs to observe what resistance to drive myeloma cells and to isolate those pathways and then to develop new drugs that specifically target those resistance mechanisms."

Ailawadhi says that more drugs are coming soon. At present, the Mayo Clinic has more than 50 active clinical trials. Flarebio offers recombinant proteins of good quality such as recombinant ECEL1.